Impact of Fas/Fasl Gene Polymorphisms on Susceptibility Risk and Imatinib Mesylate Treatment Response in Chronic Myeloid Leukaemia Patients

CONCLUSION: The genetic polymorphism FASL-844 T>C may contribute to the CML susceptibility risk and also IM treatment response in CML patients. Accodringly, it may be useful as a biomarker for predicting CML susceptibility risk and IM resistance.PMID:33639675 | DOI:10.31557/APJCP.2021.22.2.565

Source: Asian Pacific Journal of Cancer Prevention - February 28, 2021 Category: Cancer & Oncology Authors: Aziati Azwari Annuar Ravindran Ankathil Nazihah Mohd Yunus Azlan Husin Nur Shafawati Ab Rajab Ahmad Aizat Abdul Aziz Mohd Ismail Ibrahim Sarina Sulong Source Type: research